Treats insomnia characterized. ANDA 219058, held by Taro. Doxepin Hydrochloride.
As of Nov 16, 2026, ANDA 219058 (Doxepin Hydrochloride), held by Taro, was first approved by FDA on Aug 6, 2025, with 0 approved supplements and 0 published complete response letters.
Doxepin tablets is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. The clinical trials performed in support of efficacy were up to 3 months in duration.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 6, 2025 | Original application | Approved | None posted |
| Doxepin HydrochlorideEQ 3MG BASE · tablet;oral | Doxepin Hydrochloride | Rx |
| Doxepin HydrochlorideEQ 6MG BASE · tablet;oral | Doxepin Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters